Concepedia

2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes

Sandeep R. Das, Brendan M. Everett, Kim K. Birtcher, Jenifer M. Brown, James L. Januzzi, Rita R. Kalyani, Mikhail Kosiborod, Melissa Magwire, Pamela B. Morris, Joshua J. Neumiller,

Journal of the American College of Cardiology · 2020 · 468 citations · 75 references

DOIFull text

Open access

Concepts

References

75

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

The Lancet · 1998 · 20.1K citations

, , +13

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

New England Journal of Medicine · 2002 · 19K citations · Full text

, , +1

2013 ACCF/AHA Guideline for the Management of Heart Failure

Clyde W. Yancy, Mariell Jessup, Biykem Bozkurt et al. · Journal of the American College of Cardiology · 2013 · 12.6K citations

, , +14

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text

, , +15

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

R. C. Turner, Charles Fox, Matthews et al. · The Lancet · 1998 · 8.4K citations

, , +15